Epidemiology and Clinical Characteristics of Laboratory-Confirmed COVID-19 and Influenza Infections in Children: A 2015–2024 Study in Taiwan

Hao-Yuan Lee, Chien‐Chin Chen, Smith Ko, Yu‐Lung Hsu, Ee‐Chien Chang, Ying-Chuan Hsu, Mingxuan Li, Chyi-Liang Chen, Wen‐Yuan Lee, Wen-Yuan LeeMicroorganisms 2025 · DOI

TL;DR

This study provides a comprehensive comparison of COVID-19 and influenza infections in children in Taiwan from 2015 to 2024, analyzing epidemiological trends and clinical presentations across different SARS-CoV-2 variants and influenza seasons. It highlights evolving patterns, particularly increased pneumonia rates in 2024, underscoring the need for continued vigilance in pediatric respiratory illness management.

What Problem Does This Paper Address?

The COVID-19 pandemic has dramatically altered the landscape of viral infections, including those affecting children. While initial pandemic measures suppressed influenza, its resurgence, alongside evolving COVID-19 variants, presents a complex diagnostic and clinical challenge. Differentiating between these infections is crucial as they can require different management strategies. Previous studies have offered comparisons, but many have been limited in scope, focused on specific variants, or predate the most recent waves and the full impact of "immune debt" on influenza resurgence. This paper aims to fill this gap by providing a long-term, multi-variant analysis of pediatric COVID-19 and influenza in Taiwan, a region known for its strict public health interventions.

Methods

The researchers conducted a retrospective analysis of laboratory-confirmed COVID-19 and influenza cases in children hospitalized at Wei Gong Memorial Hospital in Taiwan between January 2015 and March 2024. They specifically analyzed data from children hospitalized during the Omicron BA.2.3.7 (April-July 2022), BA.5 (August-December 2022), and JN.1 (2024) COVID-19 waves, and compared these with influenza cases from 2015-2016 and 2024. COVID-19 diagnoses were made using RT-PCR or rapid antigen tests, while influenza was detected using rapid antigen tests. Clinical features, demographic data, and laboratory findings were systematically collected and compared. Statistical analyses included Pearson's chi-squared test, Fisher's exact test, logistic regression, and the Wilcoxon rank-sum test to identify significant differences.

Datasets

The study utilized data from hospitalized pediatric patients at Wei Gong Memorial Hospital in Taiwan. The dataset comprises:

  • Influenza A and B cases: From January 2015 to March 2024, with specific analysis of 2015-2016 and 2024.
  • COVID-19 cases: From January 2015 to March 2024, with specific focus on the Omicron BA.2.3.7 (April-July 2022), BA.5 (August-December 2022), and JN.1 (2024) waves.

The total number of cases analyzed were 2729 for influenza A, 974 for influenza B, and 3752 for COVID-19.

Key Insights and Ideas

  • Shifting Age Demographics: COVID-19 in children, particularly during the Omicron waves and in 2024, skewed towards younger age groups (<3 years old) compared to influenza, which showed a higher proportion of older children (6-11 years old). This suggests different transmission dynamics or susceptibility patterns.
  • Influenza's Return and Severity: The study observed a near absence of influenza during the peak COVID-19 pandemic years (2020-2022), followed by a significant resurgence in 2023 and 2024. Notably, in 2024, influenza A cases showed a higher incidence of high fever (>40°C) and prolonged fever duration compared to COVID-19.
  • Pneumonia as a Growing Concern: A critical finding is the increased rate of pneumonia in 2024 for both COVID-19 and influenza cases, exceeding rates observed in earlier periods. This highlights a potential trend of increased respiratory complications, emphasizing the need for prompt diagnosis and intervention.
  • Leukocytosis as a COVID-19 Indicator: In 2024, COVID-19 cases were significantly more likely to present with leukocytosis (elevated white blood cell count) compared to influenza, suggesting this as a potential laboratory marker for differentiating the two in pediatric patients.

Key Results

  • Case Numbers: Between 2015 and 2024, the study recorded 2729 influenza A cases (36.6%), 974 influenza B cases (13.1%), and 3752 COVID-19 cases (50.3%).
  • COVID-19 Dominance: A substantial 84.7% of COVID-19 cases occurred between May and December 2022.
  • Fever Patterns in 2024: Influenza A cases in 2024 had a significantly higher rate of high fever (>40°C) (32.9%) compared to COVID-19 (9.1%) or influenza B (3.3%).
  • Leukocytosis: COVID-19 cases in 2024 showed a higher prevalence of leukocytosis (>12,000/µL) (33.3%) compared to influenza A (12.2%) or B (0%).
  • Pneumonia Rates: Pneumonia was more prevalent in COVID-19 cases in 2024 (27.3%) than in 2022. Furthermore, pneumonia rates for influenza A (14.8%) and B (16.7%) in 2024 were higher than in 2015-2016.

Limitations and Future Work

The authors acknowledge that a primary limitation of this study is that the data were collected from a single hospital. This means the findings may not be generalizable to the entire pediatric population and would benefit from validation across diverse geographical and demographic settings. Future research could expand on these findings by investigating the impact of vaccination status on clinical presentations and outcomes, and by exploring the long-term sequelae of these infections in children. Further research into the specific mechanisms driving the increased pneumonia rates observed in 2024 would also be valuable.

Summary updated

Abstract

The COVID-19 pandemic and Taiwan's strict prevention policies from May 2020 to April 2023 significantly altered the epidemiology of viral infections. This study analyzed pediatric COVID-19 and influenza cases at Wei Gong Memorial Hospital from January 2015 to March 2024. Clinical features were compared among children hospitalized during the Omicron BA.2.3.7 (April-July 2022), Omicron BA.5 (August-December 2022), and Omicron JN.1 (2024) waves and those with influenza in 2024 and 2015-2016. Between 2015 and 2024, there were 2729 influenza A (36.6%), 974 influenza B (13.1%), and 3752 COVID-19 (50.3%) cases, with 84.7% of COVID-19 cases occurring in May-December 2022. In 2024, high fever (>40 °C) was more common in influenza A cases (32.9%) than in COVID-19 or influenza B (<i>p</i> < 0.004). Leukocytosis (>12,000/µL) was more frequent in COVID-19 cases (33.3%) than in influenza A (12.2%) or B (0%) (<i>p</i> < 0.001). Pneumonia was more prevalent in COVID-19 cases in 2024 (27.3%) than in 2022 (<i>p</i> ≤ 0.030), and pneumonia rates for influenza A (14.8%) and B (16.7%) in 2024 exceeded those in 2015-2016 (<i>p</i> ≤ 0.030). Increased pneumonia rates in 2024 emphasize the importance of vigilance and timely intervention for pediatric COVID-19 and influenza cases.
BibTeX
@inproceedings{lee2025epidemiology,
  author = {Hao-Yuan Lee and Chien‐Chin Chen and Smith Ko and Yu‐Lung Hsu and Ee‐Chien Chang and Ying-Chuan Hsu and Mingxuan Li and Chyi-Liang Chen and Wen‐Yuan Lee and Chyi-Liang Chen and Wen-Yuan Lee},
  title = {{Epidemiology and Clinical Characteristics of Laboratory-Confirmed COVID-19 and Influenza Infections in Children: A 2015–2024 Study in Taiwan}},
  booktitle = {Microorganisms},
  year = {2025},
  doi = {10.3390/microorganisms13030517},
}
Figure